Benitec Biopharma (BNTC) vs Perspective Therapeutics (CATX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Benitec Biopharma (BNTC) over the past year, losing 29.8% versus a loss of 37.9%. Over five years, CATX leads with a -56.3% price change compared with -85.7% for BNTC. Perspective Therapeutics is the larger company by market cap ($309.4 million vs $305.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | CATX |
|---|---|---|
| Share price | $8.75 | $2.71 |
| Market cap | $305.22M | $309.35M |
| 1-day change | -2.67% | +10.16% |
| YTD return | -35.04% | -1.45% |
| 1-year return | -37.94% | -29.79% |
| 5-year return | -85.66% | -56.29% |
| EPS (TTM) | $-0.98 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $6.16 |
| 52-week low | $8.52 | $1.96 |
| Distance from 52-week high | -47.79% | -56.01% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +178.06% | +353.51% |
| Average volume | 152.08K | 1.67M |
| Shares outstanding | 34.88M | 114.15M |
| Employees | 24 | 163 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
BNTC vs CATX FAQ
Which is bigger, Benitec Biopharma or Perspective Therapeutics?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $309.35M compared with $305.22M for Benitec Biopharma (BNTC).
Which stock has performed better over the past year, BNTC or CATX?
CATX returned -29.79% over the past 12 months, compared with -37.94% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Perspective Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.